

Swaminathan Padmanabhan Iyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11353241/publications.pdf>

Version: 2024-02-01

8
papers

538
citations

1478505

6
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

976
citing authors

#	ARTICLE	IF	CITATIONS
1	Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. <i>Journal of Hematology and Oncology</i> , 2014, 7, 11.	17.0	176
2	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 ⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	1.6	149
3	Phase I study of MLN8237 [®] investigational Aurora A kinase inhibitor [®] in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2014, 32, 489-499.	2.6	67
4	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	1.4	63
5	Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T ^h cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 914-917.	1.7	50
6	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 6150-6159.	7.0	27
7	Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 3027-3027.	1.4	6
8	A Retrospective Review Of Factor X Levels and Bleeding Risk In Patients With Amyloidosis. <i>Blood</i> , 2013, 122, 3603-3603.	1.4	0